Payment overview · 2025
General Payments
$686.92
30 reported records · 10 companies
Healthcare provider profile · identity verified
Dean Okimoto, MD
Allopathic & Osteopathic Physicians|Family Medicine · YORBA LINDA, CA · NPI 1912908336
Verified facts
What the public records show
CMS Open Payments records show Dean Okimoto, MD received $686.92 in general payments during 2025 across 30 reported records.
Abbott Laboratories accounted for 18.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Eliquis, Jardiance, Mounjaro, Ozempic.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Arexvy by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $129.80 | 18.9% | 6 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $127.38 | 18.5% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $94.02 | 13.7% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $90.57 | 13.2% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $60.92 | 8.9% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $45.93 | 6.7% | 3 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $41.08 | 6.0% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $40.44 | 5.9% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $39.65 | 5.8% | 2 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $17.13 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $686.92 | 30 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $129.80 | 6 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $127.38 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $94.02 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $94.02 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $60.92 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $60.92 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $45.93 | 3 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $41.08 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $39.65 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $39.65 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $30.85 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $29.73 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $29.73 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $21.09 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $20.68 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $19.35 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $19.35 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $19.35 | 1 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $17.13 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 15 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 95 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 105 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 87 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
105 | 33 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
15 | 15 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
105 | 33 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
87 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
95 | 30 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 559 | 176 |
| Levothyroxine Sodium | Levothyroxine Sodium | 479 | 133 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 399 | 139 |
| Losartan Potassium | Losartan Potassium | 374 | 113 |
| Amlodipine Besylate | Amlodipine Besylate | 320 | 98 |
| Pantoprazole Sodium | Pantoprazole Sodium | 211 | 75 |
| Metformin Hcl Er | Metformin Hcl | 185 | 68 |
| Lisinopril | Lisinopril | 176 | 55 |
| Tamsulosin Hcl | Tamsulosin Hcl | 175 | 60 |
| Valsartan | Valsartan | 146 | 46 |
| Alendronate Sodium | Alendronate Sodium | 110 | 34 |
| Allopurinol | Allopurinol | 110 | 34 |
| Omeprazole | Omeprazole | 110 | 37 |
| Synthroid | Levothyroxine Sodium | 109 | 26 |
| Jardiance | Empagliflozin | 105 | 33 |
| Furosemide | Furosemide | 100 | 32 |
| Eliquis | Apixaban | 95 | 30 |
| Simvastatin | Simvastatin | 94 | 31 |
| Finasteride | Finasteride | 93 | 29 |
| Alprazolam | Alprazolam | 88 | 20 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 88 | 28 |
| Sertraline Hcl | Sertraline Hcl | 88 | 29 |
| Carvedilol | Carvedilol | 87 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 87 | 48 |
| Ozempic | Semaglutide | 87 | 18 |
| Metoprolol Succinate | Metoprolol Succinate | 86 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 85 | 30 |
| Famotidine | Famotidine | 84 | 26 |
| Metformin Hcl | Metformin Hcl | 76 | 24 |
| Meloxicam | Meloxicam | 75 | 32 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 72 | 14 |
| Chlorthalidone | Chlorthalidone | 70 | 17 |
| Ezetimibe | Ezetimibe | 69 | 21 |
| Gabapentin | Gabapentin | 68 | 27 |
| Montelukast Sodium | Montelukast Sodium | 67 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 65 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 63 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 59 | 19 |
| Doxazosin Mesylate | Doxazosin Mesylate | 57 | 16 |
| Azithromycin | Azithromycin | 56 | 36 |
| Hydrochlorothiazide | Hydrochlorothiazide | 54 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 54 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 53 | 30 |
| Pioglitazone Hcl | Pioglitazone Hcl | 52 | 16 |
| Tramadol Hcl | Tramadol Hcl | 52 | 15 |
| Temazepam | Temazepam | 50 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 48 | 14 |
| Trazodone Hcl | Trazodone Hcl | 47 | 12 |
| Lovastatin | Lovastatin | 43 | 14 |
| Atenolol | Atenolol | 40 | 16 |
| Benazepril Hcl | Benazepril Hcl | 40 | 11 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 39 | suppressed |
| Potassium Chloride | Potassium Chloride | 39 | 14 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 36 | suppressed |
| Januvia | Sitagliptin Phosphate | 36 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 34 | suppressed |
| Lorazepam | Lorazepam | 33 | 11 |
| Sildenafil Citrate | Sildenafil Citrate | 33 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 33 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 33 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 32 | 19 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 32 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 30 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 30 | suppressed |
| Glipizide Er | Glipizide | 30 | suppressed |
| Ketoconazole | Ketoconazole | 28 | 11 |
| Methylprednisolone | Methylprednisolone | 26 | 20 |
| Warfarin Sodium | Warfarin Sodium | 26 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 25 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 24 | suppressed |
| Estradiol | Estradiol | 24 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Glipizide | Glipizide | 23 | suppressed |
| Xarelto | Rivaroxaban | 23 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 19 |
| Memantine Hcl | Memantine Hcl | 21 | suppressed |
| Naproxen | Naproxen | 21 | suppressed |
| Spironolactone | Spironolactone | 21 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 19 | suppressed |
| Celecoxib | Celecoxib | 19 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 19 | suppressed |
| Mirtazapine | Mirtazapine | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 19 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 18 | suppressed |
| Cefdinir | Cefdinir | 18 | 16 |
| Diazepam | Diazepam | 18 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 17 | suppressed |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Testosterone | Testosterone | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 15 | 15 |
| Mupirocin | Mupirocin | 15 | 13 |
| Glimepiride | Glimepiride | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 14 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 13 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Prednisone | Prednisone | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 11 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Mounjaro | Tirzepatide | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $686.92 · 30 records | Abbott Laboratories | ABRYSVO, AREXVY, BEXSERO, COMIRNATY, ELIQUIS, FREESTYLE LIBRE 3, JARDIANCE, MOUNJARO, OTEZLA, Ozempic, PREVNAR 20, REPATHA, Rybelsus, SHINGRIX, SPRAVATO, TZIELD, Tymlos, Wegovy, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error